Osanto S - Search Results

1

[Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells].

Osanto S, Brand A, van Rood JJ, Cleton FJ. Osanto S, et al. Ned Tijdschr Geneeskd. 1989 Jul 15;133(28):1392-5. Ned Tijdschr Geneeskd. 1989. PMID: 2677758 Review. Dutch. No abstract available.

2

Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.

Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, Lentjes E, Van Rood JJ, Cleton FJ, Osanto S. Weijl NI, et al. Among authors: osanto s. J Clin Oncol. 1993 Jul;11(7):1376-83. doi: 10.1200/JCO.1993.11.7.1376. J Clin Oncol. 1993. PMID: 8315436 Clinical Trial.

3

[Scintigraphic studies in the detection of cancer using anti-tumor monoclonal antibodies].

Pauwels EK, Cleton FJ, Osanto S. Pauwels EK, et al. Among authors: osanto s. Ned Tijdschr Geneeskd. 1984 Apr 28;128(17):805-9. Ned Tijdschr Geneeskd. 1984. PMID: 6717657 Dutch. No abstract available.

4

Myocardial injury after interleukin-2 therapy.

Osanto S, Cluitmans FH, Franks CR, Bosker HA, Cleton FJ. Osanto S, et al. Lancet. 1988 Jul 2;2(8601):48-9. doi: 10.1016/s0140-6736(88)92982-0. Lancet. 1988. PMID: 2898655 No abstract available.

5

Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patients.

Schaafsma MR, Fibbe WE, van der Harst D, Duinkerken N, Brand A, Osanto S, Franks CR, Willemze R, Falkenburg JH. Schaafsma MR, et al. Among authors: osanto s. Br J Haematol. 1990 Oct;76(2):180-5. doi: 10.1111/j.1365-2141.1990.tb07869.x. Br J Haematol. 1990. PMID: 2094321 Clinical Trial.

6

Free radicals and antioxidants in chemotherapy-induced toxicity.

Weijl NI, Cleton FJ, Osanto S. Weijl NI, et al. Among authors: osanto s. Cancer Treat Rev. 1997 Jul;23(4):209-40. doi: 10.1016/s0305-7372(97)90012-8. Cancer Treat Rev. 1997. PMID: 9377594 Review. No abstract available.

7

In vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma.

Osanto S, Jansen R, Naipal AM, Gratama JW, van Leeuwen A, Cleton FJ. Osanto S, et al. Int J Cancer. 1989 Jun 15;43(6):1001-6. doi: 10.1002/ijc.2910430608. Int J Cancer. 1989. PMID: 2499552 Clinical Trial.

8

Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients.

Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, Osanto S. Weijl NI, et al. Among authors: osanto s. Ann Oncol. 1998 Dec;9(12):1331-7. doi: 10.1023/a:1008407014084. Ann Oncol. 1998. PMID: 9932164 Free article. Clinical Trial.

9

Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.

Osanto S, Schiphorst PP, Weijl NI, Dijkstra N, Van Wees A, Brouwenstein N, Vaessen N, Van Krieken JH, Hermans J, Cleton FJ, Schrier PI. Osanto S, et al. Hum Gene Ther. 2000 Mar 20;11(5):739-50. doi: 10.1089/10430340050015635. Hum Gene Ther. 2000. PMID: 10757353 Clinical Trial.

10

Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature.

Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, Cleton FJ, Osanto S. Weijl NI, et al. Among authors: osanto s. J Clin Oncol. 2000 May;18(10):2169-78. doi: 10.1200/JCO.2000.18.10.2169. J Clin Oncol. 2000. PMID: 10811682 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters